Citadel Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,067,586
| Closed | -$120M | – | 14276 |
|
|
2025
Q1 | $119M | Buy |
1,067,586
+479,398
| +82% | +$51M | 0.02% | 599 |
|
|
2024
Q4 | $57.2M | Buy |
588,188
+406,007
| +223% | +$43.3M | 0.01% | 1165 |
|
|
2024
Q3 | $21M | Sell |
182,181
-64,380
| -26% | -$7.31M | ﹤0.01% | 2005 |
|
|
2024
Q2 | $26.2M | Sell |
246,561
-315,524
| -56% | -$31.7M | 0.01% | 1729 |
|
|
2024
Q1 | $54.4M | Buy |
562,085
+122,030
| +28% | +$12.5M | 0.01% | 1143 |
|
|
2023
Q4 | $44.4M | Buy |
+440,055
| New | +$42.5M | 0.01% | 1279 |
|
|
2023
Q3 | – | Sell |
-1,661
| Closed | -$169K | – | 14834 |
|
|
2023
Q2 | $168K | Buy |
1,661
+1,487
| +855% | +$149K | ﹤0.01% | 10155 |
|
|
2023
Q1 | $16K | Sell |
174
-41,591
| -100% | -$3.63M | ﹤0.01% | 13227 |
|
|
2022
Q4 | $3.79M | Sell |
41,765
-98,408
| -70% | -$8.29M | ﹤0.01% | 4344 |
|
|
2022
Q3 | $10.7M | Buy |
140,173
+77,778
| +125% | +$6.45M | ﹤0.01% | 2666 |
|
|
2022
Q2 | $5.27M | Buy |
62,395
+58,105
| +1,354% | +$5.1M | ﹤0.01% | 3697 |
|
|
2022
Q1 | $376K | Sell |
4,290
-287,988
| -99% | -$24.9M | ﹤0.01% | 10069 |
|
|
2021
Q4 | $25.6M | Buy |
292,278
+119,816
| +69% | +$9.95M | 0.01% | 1757 |
|
|
2021
Q3 | $14.1M | Sell |
172,462
-123,872
| -42% | -$11.1M | ﹤0.01% | 2512 |
|
|
2021
Q2 | $27M | Buy |
296,334
+240,836
| +434% | +$21.4M | 0.01% | 1727 |
|
|
2021
Q1 | $4.74M | Sell |
55,498
-95,723
| -63% | -$8.59M | ﹤0.01% | 4372 |
|
|
2020
Q4 | $14.3M | Buy |
151,221
+126,129
| +503% | +$11M | ﹤0.01% | 2185 |
|
|
2020
Q3 | $2.18M | Buy |
+25,092
| New | +$2.17M | ﹤0.01% | 4557 |
|
|
2020
Q2 | – | Sell |
-81,811
| Closed | -$7.06M | – | 10281 |
|
|
2020
Q1 | $6.75M | Buy |
81,811
+67,135
| +457% | +$5.99M | ﹤0.01% | 2331 |
|
|
2019
Q4 | $1.39M | Sell |
14,676
-40,413
| -73% | -$3.63M | ﹤0.01% | 5003 |
|
|
2019
Q3 | $4.79M | Sell |
55,089
-512,656
| -90% | -$46M | ﹤0.01% | 3169 |
|
|
2019
Q2 | $51.8M | Buy |
567,745
+389,451
| +218% | +$33M | 0.02% | 704 |
|
|
2019
Q1 | $15.4M | Sell |
178,294
-112,327
| -39% | -$9.02M | 0.01% | 1580 |
|
|
2018
Q4 | $22.3M | Sell |
290,621
-586,831
| -67% | -$45.7M | 0.01% | 1139 |
|
|
2018
Q3 | $67.7M | Buy |
877,452
+829,335
| +1,724% | +$61.3M | 0.03% | 589 |
|
|
2018
Q2 | $3.26M | Sell |
48,117
-33,927
| -41% | -$2.34M | ﹤0.01% | 3357 |
|
|
2018
Q1 | $5.94M | Sell |
82,044
-25,226
| -24% | -$1.92M | ﹤0.01% | 2275 |
|
|
2017
Q4 | $8.07M | Buy |
+107,270
| New | +$8.09M | ﹤0.01% | 1945 |
|
|
2017
Q3 | – | Sell |
-23,924
| Closed | -$1.81M | – | 7871 |
|
|
2017
Q2 | $1.79M | Sell |
23,924
-212,290
| -90% | -$15M | ﹤0.01% | 3318 |
|
|
2017
Q1 | $15.7M | Sell |
236,214
-1,067
| -0.4% | -$71.1K | 0.01% | 1121 |
|
|
2016
Q4 | $15.5M | Buy |
237,281
+230,759
| +3,538% | +$15M | 0.02% | 1043 |
|
|
2016
Q3 | $461K | Sell |
6,522
-24,668
| -79% | -$1.8M | ﹤0.01% | 4989 |
|
|
2016
Q2 | $2.31M | Sell |
31,190
-154,885
| -83% | -$10.7M | ﹤0.01% | 2591 |
|
|
2016
Q1 | $12.1M | Buy |
186,075
+82,911
| +80% | +$5.64M | 0.02% | 1051 |
|
|
2015
Q4 | $7.95M | Sell |
103,164
-40,513
| -28% | -$3.22M | 0.01% | 1448 |
|
|
2015
Q3 | $11.8M | Buy |
143,677
+136,093
| +1,794% | +$12.1M | 0.01% | 1234 |
|
|
2015
Q2 | $668K | Sell |
7,584
-75,363
| -91% | -$6.91M | ﹤0.01% | 4536 |
|
|
2015
Q1 | $7.33M | Buy |
82,947
+79,599
| +2,378% | +$7.06M | 0.01% | 1684 |
|
|
2014
Q4 | $278K | Hold |
3,348
| – | – | ﹤0.01% | 5552 |
|
|
2014
Q3 | $282K | Sell |
3,348
-4,841
| -59% | -$392K | ﹤0.01% | 5333 |
|
|
2014
Q2 | $664K | Sell |
8,189
-1,228
| -13% | -$96.6K | ﹤0.01% | 4007 |
|
|
2014
Q1 | $717K | Sell |
9,417
-18,693
| -66% | -$1.36M | ﹤0.01% | 3852 |
|
|
2013
Q4 | $2.02M | Buy |
28,110
+24,762
| +740% | +$1.72M | ﹤0.01% | 2541 |
|
|
2013
Q3 | $230K | Buy |
+3,348
| New | +$222K | ﹤0.01% | 4631 |
|
Other funds holding NVS
Citadel Advisors's NVS Position: Q2 2025 in Review
Citadel Advisors sold out of Novartis (NVS) in Q2 2025, closing a stake of 1,067,586 shares — an estimated $120M sold.
Citadel Advisors first reported a position in NVS in Q3 2013 and held it in 44 quarters. The position peaked at $119M in Q1 2025. 1,383 funds tracked by Wall St. Rank hold NVS as of Q2 2025.
- Citadel Advisors reported no remaining Novartis position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 1,067,586 Novartis shares in Q2 2025, an estimated $120M.
- Citadel Advisors first reported a position in Novartis in Q3 2013 and held it in 44 quarters.
- Citadel Advisors's Novartis position peaked at $119M in Q1 2025.
- 1,383 funds tracked by Wall St. Rank held Novartis as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.